Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 1,629 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: In The Mix Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Mixed-Methods Evaluation of Short-, Medium-, and Long-Term Outcomes Following Hip Treatment

NCT06891196
View directory record Official record
Conditions
Hip Dysplasia, Legg-Calvâe-Perthes Disease, Avascular Necrosis of Hip
Interventions
Long-term Follow-up Surveys
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

NCT04254783
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn's Disease
Interventions
Risankizumab, Cytochrome P450 (CYP) Substrates
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Coronado, California • DeLand, Florida • Margate, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Phase 1 Interventional

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

NCT00049296
View directory record Official record
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 30, 2026, 11:16 PM EDT
Recruiting Not applicable Interventional

A Virtual Life Story Club Intervention to Improve Loneliness and Apathy in Community-Dwelling Older Adults

NCT06919094
View directory record Official record
Conditions
Apathy, Loneliness, Reminiscence Therapy
Interventions
Life Story Club
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
60 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer

NCT01580696
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Fallopian Cancer, Peritoneal Cancer
Interventions
E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster, Non-vaccine clinically matched control group, E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster, E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster, E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster, E39 peptide (500mcg)/GM-CSF vaccine plus J65 booster, E39 peptide (1000mcg)/GM-CSF vaccine plus J65 booster
Biological · Other
Lead sponsor
COL George Peoples, MD, FACS
Federal
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Annandale, Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 30, 2026, 11:16 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Ovarian Function Following Intraovarian Injection of PRP

NCT04278313
View directory record Official record
Conditions
Diminished Ovarian Reserve, Diminished Ovarian Reserve Due to Advanced Maternal Age
Interventions
PRP - Platelet Rich Plasma, PPP - Platelet Poor Plasma
Procedure
Lead sponsor
Center for Human Reproduction
Other
Eligibility
21 Years to 44 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Terminated Phase 3 Interventional Results available

Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease

NCT00642616
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Moderate Chronic Obstructive Pulmonary Disease, Asthma
Interventions
Technosphere® Insulin, Usual Care
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
12
States / cities
Mission Hills, California • San Diego, California • Palm Harbor, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Suprazygomatic Maxillary Nerve Block in Cleft Palate Outcomes

NCT04909619
View directory record Official record
Conditions
Cleft Palate Children
Interventions
Ultrasound-guided bilateral suprazygomatic maxillary nerve block, Local anesthetic infiltration of the palate
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
9 Months to 2 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Active, not recruiting Phase 2 Interventional

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

NCT05340309
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Atezolizumab and Recombinant Human Hyaluronidase, Survey Administration
Biological · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The EFFECT Study: Probiotic and HMO Supplementation in Infants

NCT03994315
View directory record Official record
Conditions
Infant Gut Microbiome
Interventions
B. infantis EVC001, Lacto-N-tetraose (LNT)
Other
Lead sponsor
Evolve BioSystems, Inc.
Industry
Eligibility
Up to 60 Days
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Phase 2 Interventional Results available

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

NCT00691015
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
rituximab, busulfan, carmustine, cyclophosphamide, cytarabine, etoposide, fludarabine phosphate, melphalan, total body irradiation (TBI), anti-thymocyte globulin IV
Biological · Drug · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 30, 2026, 11:16 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Rejuvenated RBC and VO2 Max in Healthy Subjects

NCT03089047
View directory record Official record
Conditions
Erythrocyte Transfusion
Interventions
Transfusion of rejuvenated and washed autolgous RBCs, Transfusion of washed autolgous RBCs
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 40 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

NCT05760313
View directory record Official record
Conditions
Functional Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Months to 23 Months
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia

NCT00245388
View directory record Official record
Conditions
Dyslipidemia
Interventions
Muraglitazar
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
53
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Irvine, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology

NCT03014310
View directory record Official record
Conditions
Avian Influenza
Interventions
AS03, MF59, Monovalent Influenza A/H5N8 vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
7
States / cities
Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of an Arabinogalactan Product

NCT04005924
View directory record Official record
Conditions
Postprandial Blood Glucose
Interventions
arabinogalactan
Other
Lead sponsor
Biofortis, Merieux NutriSciences
Industry
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 30, 2026, 11:16 PM EDT
Terminated Phase 1 Interventional

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

NCT01643603
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Lymphoid Leukemia
Interventions
Dasatinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 30, 2026, 11:16 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Mechanisms of Hypoglycemia in Patients Without Diabetes

NCT04428723
View directory record Official record
Conditions
Hypoglycemia
Interventions
Entry of demographic and medical history data into a deidentified database, Blood sample for DNA analysis, Stool sample for microbiome analysis, Mixed meal tolerance test, Continuous glucose monitoring, activity monitor
Other · Genetic · Diagnostic Test
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dietary Supplement With and Without a Probiotic

NCT04433208
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
Complex oligosaccharide, Probiotic, PPI, H2 Blocker
Dietary Supplement · Other
Lead sponsor
Prolacta Bioscience
Industry
Eligibility
18 Years to 44 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Phase 2 Interventional

Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma

NCT00005976
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carboplatin, pyrazoloacridine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
22
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 30, 2026, 11:16 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Investigating the Evolutionary Impact of Metabolic Flexibility on Physical Activity-Dependent BDNF and Cognition: Insights From the Val66Met Polymorphism

NCT07218497
View directory record Official record
Conditions
Cognition, BDNF
Interventions
d-beta-hydroxybutrate, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 35 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 30, 2026, 11:16 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

NCT07140913
View directory record Official record
Conditions
Mania, Bipolar Disorder
Interventions
Xanomeline/Trospium Chloride, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 30, 2026, 11:16 PM EDT
Completed No phase listed Observational Results available

COVID-19 Screening Program

NCT05216627
View directory record Official record
Conditions
COVID-19
Interventions
Self-administered saliva-based viral testing
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 30, 2026, 11:16 PM EDT
Completed Phase 1 Interventional

Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme

NCT02017249
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
arginine in powder form, Silica and cellulose placebo powder
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 30, 2026, 11:16 PM EDT